The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment

Background In 1975–99, only 1·1% of new therapeutic products had been developed for neglected diseases. Since then, several public and private initiatives have attempted to mitigate this imbalance. We analysed the research and development pipeline of drugs and vaccines for neglected diseases from 2000 to 2011. Methods We searched databases of drug regulatory authorities, WHO, and clinical trial registries for entries made between Jan 1, 2000, and Dec 31, 2011. We defi ned neglected diseases as malaria, tuberculosis, diarrhoeal diseases, neglected tropical diseases (NTDs; WHO defi nition), and other diseases of poverty according to common defi nitions. Findings Of the 850 new therapeutic products registered in 2000–11, 37 (4%) were indicated for neglected diseases, comprising 25 products with a new indication or formulation and eight vaccines or biological products. Only four new chemical entities were approved for neglected diseases (three for malaria, one for diarrhoeal disease), accounting for 1% of the 336 new chemical entities approved during the study period. Of 148 445 clinical trials registered in Dec 31, 2011, only 2016 (1%) were for neglected diseases. Interpretation Our fi ndings show a persistent insuffi ciency in drug and vaccine development for neglected diseases. Nevertheless, these and other data show a slight improvement during the past 12 years in new therapeutics development and registration. However, for many neglected diseases, new therapeutic products urgently need to be developed and delivered to improve control and potentially achieve elimination

Pharmacie hospitalière au Burkina Faso (analyse et besoins en formation spécialisée)

L efficience du système de santé d un pays et sa capacité à répondre aux besoins de la population dépend en partie de la capacité de ses pharmaciens à fournir, dispenser et promouvoir l usage rationnel des médicaments. L objet de cette étude était de décrire et d analyser la Pharmacie Hospitalière (PH) au Burkina Faso, en vue de définir ses perspectives et ses nécessités et de proposer une amélioration par l instauration d une formation spécialisée. Matériels et méthode : une grille de recueil a permis de rassembler les données sur la PH au Burkina Faso dans les 3 CHU et les 9 CHR. Résultats-Discussion : les 12 PH réalisent les activités de base du pharmacien hospitalier : achat, gestion des stocks... Mais ces activités sont marquées par une utilisation inadéquate des médicaments liée au manque d information pharmaceutique et à l absence de comité thérapeutique. En effet, 1 seul CHU dispose d un comité thérapeutique pour le bon usage du médicament. Les autres activités sont plus ou moins effectives selon les PH. Le manque de professionnels disposant du profil de compétence adapté aux activités qui leur sont réservées, ne permet pas la réalisation optimale des activités dans les PH. Aussi proposons-nous une amélioration par la mise en place d une formation spécialisée en PH basée sur la pratique, qui leur permettra de réaliser de façon efficiente les différentes tâches qui leur incombent. Conclusion : la PH au Burkina Faso n est pas encore efficiente. Nous proposons une amélioration par l instauration d une formation spécialisée, d autant plus que cette initiative pourra bénéficier d appuis extérieurs.GRENOBLE1-BU Médecine pharm. (385162101) / SudocSudocFranceF

The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment

Background: In 1975–99, only 1·1% of new therapeutic products had been developed for neglected diseases. Since then, several public and private initiatives have attempted to mitigate this imbalance. We analysed the research and development pipeline of drugs and vaccines for neglected diseases from 2000 to 2011. Methods: We searched databases of drug regulatory authorities, WHO, and clinical trial registries for entries made between Jan 1, 2000, and Dec 31, 2011. We defined neglected diseases as malaria, tuberculosis, diarrhoeal diseases, neglected tropical diseases (NTDs; WHO definition), and other diseases of poverty according to common definitions. Findings: Of the 850 new therapeutic products registered in 2000–11, 37 (4%) were indicated for neglected diseases, comprising 25 products with a new indication or formulation and eight vaccines or biological products. Only four new chemical entities were approved for neglected diseases (three for malaria, one for diarrhoeal disease), accounting for 1% of the 336 new chemical entities approved during the study period. Of 148 445 clinical trials registered in Dec 31, 2011, only 2016 (1%) were for neglected diseases. Interpretation: Our findings show a persistent insufficiency in drug and vaccine development for neglected diseases. Nevertheless, these and other data show a slight improvement during the past 12 years in new therapeutics development and registration. However, for many neglected diseases, new therapeutic products urgently need to be developed and delivered to improve control and potentially achieve elimination. Funding: None